US Bancorp’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $204K | Buy |
12,035
+31
| +0.3% | +$495 | ﹤0.01% | 2096 |
|
|
2026
Q1 | $178K | Buy |
12,004
+44
| +0.4% | +$643 | ﹤0.01% | 2081 |
|
|
2025
Q4 | $191K | Hold |
11,960
| – | – | ﹤0.01% | 2053 |
|
|
2025
Q3 | $132K | Sell |
11,960
-41
| -0.3% | -$448 | ﹤0.01% | 2217 |
|
|
2025
Q2 | $102K | Buy |
12,001
+19
| +0.2% | +$152 | ﹤0.01% | 2411 |
|
|
2025
Q1 | $96.3K | Sell |
11,982
-7,384
| -38% | -$59.8K | ﹤0.01% | 2418 |
|
|
2024
Q4 | $174K | Buy |
19,366
+7,406
| +62% | +$60.4K | ﹤0.01% | 2095 |
|
|
2024
Q3 | $87.7K | Buy |
11,960
+382
| +3% | +$2.37K | ﹤0.01% | 2456 |
|
|
2024
Q2 | $66.1K | Buy |
11,578
+2,758
| +31% | +$14.5K | ﹤0.01% | 2529 |
|
|
2024
Q1 | $44.2K | Sell |
8,820
-1,158
| -12% | -$7.86K | ﹤0.01% | 2759 |
|
|
2023
Q4 | $89.7K | Buy |
9,978
+1,158
| +13% | +$9.54K | ﹤0.01% | 2394 |
|
|
2023
Q3 | $68.5K | Hold |
8,820
| – | – | ﹤0.01% | 2306 |
|
|
2023
Q2 | $85.4K | Sell |
8,820
-539
| -6% | -$5.59K | ﹤0.01% | 2264 |
|
|
2023
Q1 | $103K | Buy |
9,359
+539
| +6% | +$4.75K | ﹤0.01% | 2176 |
|
|
2022
Q4 | $38.1K | Hold |
8,820
| – | – | ﹤0.01% | 2671 |
|
|
2022
Q3 | $66K | Hold |
8,820
| – | – | ﹤0.01% | 2392 |
|
|
2022
Q2 | $89K | Hold |
8,820
| – | – | ﹤0.01% | 2295 |
|
|
2022
Q1 | $109K | Hold |
8,820
| – | – | ﹤0.01% | 2253 |
|
|
2021
Q4 | $202K | Sell |
8,820
-288
| -3% | -$6.82K | ﹤0.01% | 1969 |
|
|
2021
Q3 | $202K | Hold |
9,108
| – | – | ﹤0.01% | 1961 |
|
|
2021
Q2 | $118K | Buy |
9,108
+88
| +1% | +$1.12K | ﹤0.01% | 2215 |
|
|
2021
Q1 | $117K | Buy |
9,020
+200
| +2% | +$2.9K | ﹤0.01% | 2183 |
|
|
2020
Q4 | $122K | Hold |
8,820
| – | – | ﹤0.01% | 2113 |
|
|
2020
Q3 | $130K | Hold |
8,820
| – | – | ﹤0.01% | 1964 |
|
|
2020
Q2 | $143K | Hold |
8,820
| – | – | ﹤0.01% | 1931 |
|
|
2020
Q1 | $128K | Hold |
8,820
| – | – | ﹤0.01% | 1897 |
|
|
2019
Q4 | $179K | Hold |
8,820
| – | – | ﹤0.01% | 1886 |
|
|
2019
Q3 | $47K | Hold |
8,820
| – | – | ﹤0.01% | 2498 |
|
|
2019
Q2 | $58K | Hold |
8,820
| – | – | ﹤0.01% | 2453 |
|
|
2019
Q1 | $57K | Hold |
8,820
| – | – | ﹤0.01% | 2429 |
|
|
2018
Q4 | $60K | Sell |
8,820
-5,000
| -36% | -$28.8K | ﹤0.01% | 2362 |
|
|
2018
Q3 | $92K | Buy |
+13,820
| New | +$77.5K | ﹤0.01% | 2258 |
|
Other funds holding AUPH
TCM
NMC
US Bancorp's AUPH Position: Q2 2026 in Review
US Bancorp increased its Aurinia Pharmaceuticals (AUPH) stake by 0.26% in Q2 2026, buying an estimated $495 and bringing the position to 12,035 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #2096.
US Bancorp first reported a position in AUPH in Q3 2018 and has held it in 32 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.
- US Bancorp held 12,035 shares of Aurinia Pharmaceuticals worth $204K as of Q2 2026.
- US Bancorp bought 31 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $495.
- Aurinia Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2096 holding.
- US Bancorp first reported a position in Aurinia Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.